Ambroxol hydrochloride - CAS 23828-92-4
Catalog number: 23828-92-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C13H18Br2N2O.HCl
Molecular Weight:
414.56
COA:
Inquire
Targets:
Sodium channel
Description:
AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, inhibits TTX-resistant Na+ currents with IC50 of 35.2 μM and 22.5 μM for tonic and phasic block, inhibits TTX-sensitive Na+ currents with IC50 of 100 μM. It is used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Ambolar, and Lysopain.
Purity:
>98%
Synonyms:
Ambroxol hydrochloride
MSDS:
Inquire
InChIKey:
QNVKOSLOVOTXKF-UHFFFAOYSA-N
InChI:
InChI=1S/C13H18Br2N2O.ClH/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10;/h5-6,10-11,17-18H,1-4,7,16H2;1H
Canonical SMILES:
C1CC(CCC1NCC2=CC(=CC(=C2N)Br)Br)O.Cl
1.Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer.
Wang X1, Wang L, Wang H, Zhang H. Cell Biochem Biophys. 2015 Mar 4. [Epub ahead of print]
The purpose is to observe the clinical effect of large doses of ambroxol hydrochloride in lung protection during the perioperative period of lung cancer operation. Fifty-six lung cancer patients who have undergone open-thoracic pulmonary lobectomy were divided randomly into two groups, and were given normal and large doses of ambroxol hydrochloride, respectively, during their perioperative period. Statistics based on post-operation clinical observations were analyzed in terms of ease of expectoration and expectoration properties, duration of antibiotics dependence, occurrence of lung complications, and adverse reactions related to ambroxol hydrochloride. On the third and the seventh day, the experimental group showed signs of improvement in terms of ease of expectoration and expectoration properties, compared with the controlled group. In terms of occurrence of post-operation lung complications and duration of antibiotics dependence, the experimental group also performed better.
2.Gastro retention using polymer cocoons.
Arnold J1, Hunkeler D. Artif Cells Nanomed Biotechnol. 2015 Feb;43(1):26-32. doi: 10.3109/21691401.2014.940084. Epub 2014 Jul 31.
A gastro-retentive capsule has been prepared which is retained in the stomach for a period of 24h, providing a vehicle for the controlled delivery to the upper intestines. These "gastro cocoons" can resist passage through the sphincter of the stomach, and can retain a high drug payload (30%). They are made from oppositely charged polyelectrolytes and can swell to twice their initial volume. They are strong and also can resist 550 N of compressive force. They are based on filled pharmaceutical capsules which are visible to X-rays. Using ambroxol hydrochloride as a model drug linear, zero-order, release curves were obtained.
3.Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial.
Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z. Pharmazie. 2014 Nov;69(11):842-9.
This study aimed to compare the efficacy and safety of letosteine and ambroxol hydrochloride for the treatment of sputum thickening and expectoration difficulty due to either acute or chronic respiratory diseases. Patients (n = 240) were randomized to receive either letosteine + placebo (50 mg thrice daily, Group A) or ambroxol hydrochloride + placebo (30 mg thrice daily, Group B) orally for 5-14 days. The primary outcomes comprised the total effectiveness rate and the total improvement rate. Secondary outcomes included: post-treatment IgA level changes and post-treatment therapeutic evaluation scoring of clinical symptoms. The full analysis set (FAS) comprised 113 patients in Group A and 116 in Group B. The total effectiveness rates were 95.58% for Group A and 95.69% for Group B. The total improvement rates were 99.12% and 99.14% for Group A and Group B, respectively. There were no significant differences between the two groups for any of the primary or secondary outcomes in either the FAS or the per protocol populations (PPS; all P-values > 0.
4.Validated derivative and ratio derivative spectrophotometric methods for the simultaneous determination of levocetirizine dihydrochloride and ambroxol hydrochloride in pharmaceutical dosage form.
Ali OI1, Ismail NS2, Elgohary RM2. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 15;153:605-11. doi: 10.1016/j.saa.2015.09.014. Epub 2015 Sep 25.
Three simple, precise, accurate and validated derivative spectrophotometric methods have been developed for the simultaneous determination of levocetirizine dihydrochloride (LCD) and ambroxol hydrochloride (ABH) in bulk powder and in pharmaceutical formulations. The first method is a first derivative spectrophotometric method ((1)D) using a zero-crossing technique of measurement at 210.4 nm for LCD and at 220.0 nm for ABH. The second method employs a second derivative spectrophotometry ((2)D) where the measurements were carried out at 242.0 and 224.4 nm for LCD and ABH, respectively. In the third method, the first derivative of the ratio spectra was calculated and the first derivative of the ratio amplitudes at 222.8 and 247.2 nm was selected for the determination of LCD and ABH, respectively. Calibration graphs were established in the ranges of 1.0-20.0 μg mL(-1) for LCD and 4.0-20.0 μg mL(-1) for ABH using derivative and ratio first derivative spectrophotometric methods with good correlation coefficients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


Elzasonan hydrochloride
(CAS: 220322-05-4)

Elzasonan, also called as CP 448187, exhibits potent and selective antagonism of 5-HT1B receptors in vitro, and preclinical in vivo studies demonstrate enhanced...

CAS 154355-76-7 Atreleuton

Atreleuton
(CAS: 154355-76-7)

Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...

CAS 175340-20-2 S 18986

S 18986
(CAS: 175340-20-2)

S 18986 is a positive allosteric modulator of AMPA receptors that enhances (S)-AMPA-mediated noradrenaline release in rat hippocampal and frontal cortex slices....

CAS 10540-29-1 Tamoxifen

Tamoxifen
(CAS: 10540-29-1)

Tamoxifen, a selective estrogen response modifier, is used in the advanced treatment of breast and ovarian cancer for it could be metabolized to two active ingr...

CAS 796888-12-5 LCH-7749944

LCH-7749944
(CAS: 796888-12-5)

LCH-7749944, also known as GNF-Pf-2356, is a novel and potent PAK4 inhibitor, which effectively suppresses the proliferation of human gastric cancer cells thro...

CAS 562-10-7 Doxylamine Succinate

Doxylamine Succinate
(CAS: 562-10-7)

Doxylamine succinate competitively inhibits histamine at H1 receptors with substantial sedative and anticholinergic effects.

CAS 209394-46-7 Ladostigil tartrate

Ladostigil tartrate
(CAS: 209394-46-7)

Ladostigil, also called as TV-3,326, is a novel neuroprotective agent developed to treat neurodegenerative disorders sunch as Alzheimer’s disease. Ladostigil is...

CAS 3543-75-7 Bendamustine hydrochloride

Bendamustine hydrochloride
(CAS: 3543-75-7)

Bendamustine hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Be...

Chemical Structure

CAS 23828-92-4 Ambroxol hydrochloride

Quick Inquiry

Verification code

Featured Items